“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
The revolution in cancer drug development has a caveat: Only a fraction of eligible patients take part in clinical trials. Historically, findings from studies estimate that the share of eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback